Hospira, a pharmaceutical and medical device manufacturer based in Lake Forest, Illinois, signed a new deal with Q Core Medical for distribution of its Sapphire infusion pump. The latest deal follows a recent ban on imports of Hospira’s Symbiq infusion pumps by the United States Food and Drug Administration.
According to a press release by Hospira, financial details of the agreement aren’t available. However, Hospira will be able to sell Q Core’s infusion pump device in 60 different markets around the world. The deal will also allow both companies to collaborate on devices in the future.
While the new deal is good for Hospira, the company still has issues that must be resolved. While the Q Core Sapphire infusion pump doesn’t have an FDA import ban like Hospira’s Symbiq, the Sapphire system still doesn’t have FDA approval. Hospira stated that it is actively pursuing FDA approval of Q Core’s Sapphire infusion pump.
Julie Sawyer Montgomery is the vice president of Hospira. In prepared remarks, she said, "Collaborating with Q Core reinforces Hospira's commitment to providing advanced infusion systems that help improve the safety and efficiency of I.V. medication administration." She continued, "With clinicians in multiple regions using the Sapphire system to support their medication administration needs, the device expands Hospira's ability to help support patient safety in key geographies."